Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program
Status:
RECRUITING
Trial end date:
2029-10-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to test daratumumab in adult very high risk T-lineage lymphoblastic leukemia.
The main question it aims to answer is wether the addition of daratumumab daratumumab to the national standard of care is able to increase the rate of MRD-negative patients after induction therapy.
Participants will be treated with:
• daratumumab in combination with a pediatric-inspired treatment scheme - as in the previous GIMEMA LAL1913 protocol.